-
1.发明公开HUMAN CORD BLOOD AS A SOURCE OF NEURAL TISSUE FOR REPAIR OF THE BRAIN AND SPINAL CORD 审中-公开脐血AS愈合和脑脊髓神经组织源
公开(公告)号：EP1263930A1
公开(公告)日：2002-12-11
申请号：EP01916437.5
申请日：2001-03-07
CPC分类号： A61K35/30 , A61K35/12 , A61K35/51 , A61K2035/124 , C12N5/0618 , C12N2501/13 , C12N2501/385 , C12N2506/1369
摘要： The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
-
公开(公告)号：EP1139744A1
公开(公告)日：2001-10-10
申请号：EP99967396.5
申请日：1999-12-16
发明人： SHYTLE, Douglas , SANBERG, Paul , NEWMAN, Mary , SILVER, Archie
CPC分类号： A61K31/13 , A61K9/0019 , A61K31/015 , C07D401/04
摘要： A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorders, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
-
公开(公告)号：EP1139743B1
公开(公告)日：2006-03-22
申请号：EP99967401.3
申请日：1999-12-16
发明人： SHYTLE, Douglas , SANBERG, Paul , NEWMAN, Mary , SILVER, Archie
IPC分类号： A01N33/18 , A01N33/24 , A61K31/13 , A61K31/015 , C07C209/88 , C07D217/26
CPC分类号： A61K31/13 , A61K9/0019 , A61K31/015 , C07D401/04
摘要： A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
-
公开(公告)号：EP2134182A2
公开(公告)日：2009-12-23
申请号：EP06839782.7
申请日：2006-11-08
发明人： ROBERT, J., Henning , SANBERG, Paul
CPC分类号： A61K35/51
摘要： A method of treating acute myocardial infarction has the steps of providing human umbilical cord blood cells (HUCBC); and administering the HUCBC to the individual with the acute myocardial infarction at particular time intervals after said myocardial infarction. Preferably the intervals are about one to about three hours or about 12 to about 48 hours after the acute myocardial infarction.
-
公开(公告)号：EP1139743A1
公开(公告)日：2001-10-10
申请号：EP99967401.3
申请日：1999-12-16
发明人： SHYTLE, Douglas , SANBERG, Paul , NEWMAN, Mary , SILVER, Archie
IPC分类号： A01N33/02
CPC分类号： A61K31/13 , A61K9/0019 , A61K31/015 , C07D401/04
摘要： A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
摘要翻译： 药物组合物包含治疗有效量的基本上不含外-R-美卡拉米的外-S-美卡拉明或其药学上可接受的盐以及药学上可接受的载体。 优选的量为约0.5mg至约20mg。 通过施用治疗有效量的基本上不含其外型-R-美卡拉明的外-s-美卡拉明或其药学上可接受的盐来治疗医疗状况，所述量足以改善医疗状况。 医疗条件包括但不限于物质成瘾（涉及尼古丁，可卡因，酒精，苯丙胺，鸦片，其他精神兴奋剂及其组合），帮助戒烟，治疗与戒烟有关的体重增加，高血压，高血压危象，图雷特综合征 （例如小细胞肺癌），致动脉粥样硬化分布，神经精神障碍（例如双相性精神障碍，抑郁症，焦虑症，精神分裂症，癫痫发作障碍，帕金森病和注意力缺陷多动障碍），慢性疲劳综合症， 克罗恩病，自主神经反射异常和痉挛性肠道疾病。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
